Aim: Icodextrin reduces glucose absorption from the peritoneal dialysate. We conducted this prospective, open-labeled, multicenter study to determine the effects of icodextrin on glycemic and lipid parameters in diabetic patients undergoing continuous ambulatory peritoneal dialysis (PD) or automated PD. Methods: Patients were recruited from 15 institutions in Japan, and a total of 51 patients (15 women and 36 men, mean age: 59 ± 10 years, median duration of PD: 13 months) were enrolled. The patients were administered an overnight or daytime dwell of 1.5 or 2.0 l of 7.5% icodextrin-containing solution. At baseline and 3, 6, 9 and 12 months after the start of icodextrin, nonfasting blood was drawn for measurement of glycated hemoglobin (HbA1C) and serum lipids. Results: During icodextrin treatment, there was no change in overall HbA1C levels compared to baseline values; however, for those with baseline HbA1C ≧6.5% (n = 22), significant decreases in HbA1C were observed. Mean total/LDL cholesterol and triglycerides were decreased significantly during icodextrin treatment, with greater decreases for patients with baseline total cholesterol ≧220 mg/dl, LDL cholesterol ≧120 mg/dl or triglycerides ≧150 mg/dl. HDL cholesterol did not differ at any time point; however, values for patients with baseline HDL cholesterol <40 mg/dl tended to increase with marginal significance. Conclusions: In the current study, switching from glucose-containing dialysis solution to icodextrin resulted in improved lipid profiles and possibly a favorable metabolic profile, particularly in patients with poor glycemic control. These hypotheses remain to be proven in controlled clinical trials.

1.
United States Renal Data System: Annual Data Report, 2004. Minneapolis, USRDS Coordinating Center, 2004.
2.
Gejyo F, Saito A, Akizawa T, et al: Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004;5:443–459.
3.
Kraus MA, Hamburger RJ: Is peritoneal dialysis the preferred modality in the diabetic patient? Adv Perit Dial 1996;12:89–92.
4.
Babazono T, Miyamae M, Tomonaga O, Omori Y: Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial 1996;12:120–125.
5.
Lee HB, Chung SH, Chu WS, Kim JK, Ha H: Peritoneal dialysis in diabetic patients. Am J Kidney Dis 2001;38(suppl 1):S200–S203.
6.
Wu MS, Yu CC, Wu CH, Haung JY, Leu ML, Huang CC: Pre-dialysis glycemic control is an independent predictor of mortality in type II diabetic patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999;19(suppl 2):S179–S183.
7.
Morioka T, Emoto M, Tabata T, et al: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909–913.
8.
Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ: Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 1998;9:1931–1939.
9.
Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA; The Dextrin in APD in Amsterdam (DIANA) Group: Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. Perit Dial Int 2000;20(suppl 2):S106–S113.
10.
Johnson DW, Arndt M, O’Shea A, Watt R, Hamilton J, Vincent K: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001;2:2.
11.
Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003;64:1480–1486.
12.
Hithaishi C, Lobbedez T, Padmanabhan S, Pineda ME, Oreopoulos DG: No beneficial effect of icodextrin on blood glucose control. Perit Dial Int 2004;24:199–200.
13.
Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A: Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005;23:303–310.
14.
Nakamura M, Taniguchi Y, Yamamoto M, Hino K, Manabe M: Homologous assay for LDL-cholesterol on an automatic analyzer. Clin Chem 1997;43:260–261.
15.
Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW: Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981;19:564–567.
16.
Collier RO Jr, Baker FB: Some Monte Carlo results on the power of the F-test under permutation in the simple randomized block design. Biometrika 1966;53:199–203.
17.
Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R: Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001;21:275–281.
18.
Moberly JB, Mujais S, Gehr T, et al: Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int 2002;62(suppl 81):S23–S33.
19.
Gokal R, Moberly J, Lindholm B, Mujais S: Metabolic and laboratory effects of icodextrin. Kidney Int 2002;62(suppl 81):S62–S71.
20.
Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. Diabet Med 2001;18:360–363.
21.
Camargo JL, Gross JL: Conditions associated with very low values of glycohemoglobin measured by an HPLC method. J Clin Pathol 2004;57:346–349.
22.
Nakao T, Matsumoto H, Okada T, et al: Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826–830.
23.
Herruer MH, van Kooten EA, Sluiter HE, Zuijderhoudt FM: Influence of uremia on the determination of blood glycohemoglobin by HPLC, electrophoresis and affinity chromatography in diabetic and non-diabetic patients. Eur J Clin Chem Clin Biochem 1994;32:361–364.
24.
Lamb E, Venton TR, Cattell WR, Dawnay A: Serum glycated albumin and fructosamine in renal dialysis patients. Nephron 1993;64:82–88.
25.
Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P: Dialysis modalities and dyslipidemia. Kidney Int 2003;63(suppl 84):S110–S112.
26.
Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P: Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002;22:220–228.
27.
Sisca S, Maggiore U: Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients. Perit Dial Int 2002;22:727–729.
28.
Wheeler DC: Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996;50(suppl 56):S41–S46.
29.
Teno S, Uto Y, Nagashima H, et al: Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401–1406.
30.
Iso H, Naito Y, Sato S, et al: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001;153:490–499.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.